Advertisement
BMY vs GSK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. GSK plc (GSK) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) maintains a larger market capitalization than GSK plc (GSK) and has delivered stronger year-to-date price gains amid portfolio momentum.
- Both companies operate in the pharmaceuticals sector with exposure to oncology, immunology, and specialty medicines, though their growth drivers differ in emphasis.
- Recent weeks saw BMY benefit from positive clinical data and raised full-year guidance following solid second-quarter results.
- GSK reported core earnings growth and announced restructuring to accelerate its late-stage pipeline, accompanied by an analyst upgrade in recent market activity.
- Relative performance highlights trade-offs between BMY’s scale and dividend stability versus GSK’s focus on cost discipline and business development.
- Market sentiment for both remains tied to pipeline execution and patent-cliff management in the broader healthcare environment.
Introduction
Investors and traders often compare Bristol-Myers Squibb (BMY) and GSK plc (GSK) to evaluate relative positioning within the large-cap pharmaceuticals industry. Both firms develop and commercialize prescription medicines across oncology, immunology, and other therapeutic areas, making them relevant benchmarks for sector exposure. This comparison appeals to those seeking insights into how differences in scale, pipeline focus, and recent operational updates influence stock behavior. Market participants monitoring healthcare equities may find the analysis useful for understanding performance contrasts in the current environment without relying on forward projections.
Bristol-Myers Squibb (BMY) Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on oncology, immunology, and cardiovascular treatments. In recent weeks, the stock has reflected broader market activity with a modest pullback over the past month following earlier gains. Year-to-date performance remains positive, supported by second-quarter revenue growth of approximately 6 percent and an upward revision to full-year guidance. Key influences include durable efficacy data for Sotyktu in psoriatic arthritis and continued momentum in the growth portfolio. Sentiment has been shaped by pipeline advancements and dividend declarations, contributing to relative stability amid sector volatility.
GSK plc (GSK) Overview and Recent Performance
GSK plc (GSK) is a UK-based pharmaceutical company with strengths in specialty medicines, vaccines, and oncology. Recent market activity shows the shares trading near multi-week levels after modest daily movements. The company delivered core earnings growth in its second-quarter results and outlined a restructuring program to accelerate research and development. Influences on performance include business development activity and an analyst upgrade with a higher price target. Sentiment has responded to pipeline progress and margin outlook improvements, providing a counterbalance to ongoing efforts to manage upcoming patent expirations.
Trending AI Robots
Tickeron’s Trending AI Robots page curates select AI trading bots from hundreds available that trade thousands of different tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section. Available bots exhibit varied trading styles, strategies, timeframes, performance metrics, and ticker sets, with statistics ranging across different risk profiles and historical outcomes. Users can explore these options to identify tools aligned with specific objectives. Review the Trending AI Robots page for additional details.
Head-to-Head Comparison
Bristol-Myers Squibb (BMY) operates with greater scale, reflected in a higher market capitalization and broader revenue base compared with GSK plc (GSK). Growth drivers for BMY center on its established oncology and immunology assets, while GSK emphasizes specialty medicines and vaccines alongside targeted acquisitions. Recent momentum favors BMY through raised guidance and clinical readouts, whereas GSK has highlighted cost-saving initiatives and R&D acceleration. Risk factors include patent expirations for both, though exposure varies by product concentration. Sector sentiment remains influenced by regulatory and pricing dynamics, creating trade-offs between BMY’s dividend consistency and GSK’s restructuring flexibility.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent portfolio momentum, and relative positioning, Tickeron’s AI would likely assign a modest probabilistic preference to Bristol-Myers Squibb (BMY) in the current environment. This assessment draws from stronger year-to-date returns and guidance updates, balanced against GSK plc (GSK)’s pipeline initiatives and analyst support. Outcomes remain subject to evolving market conditions and company-specific developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and GSK is a Buy.
BMY | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 82 | 52 | |
SMR RATING 1..100 | 22 | 34 | |
PRICE GROWTH RATING 1..100 | 44 | 58 | |
P/E GROWTH RATING 1..100 | 65 | 55 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (42). This means that GSK’s stock grew somewhat faster than BMY’s over the last 12 months.
GSK's Profit vs Risk Rating (52) in the Pharmaceuticals Major industry is in the same range as BMY (82). This means that GSK’s stock grew similarly to BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is in the same range as GSK (34). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
BMY's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as GSK (58). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
GSK's P/E Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as BMY (65). This means that GSK’s stock grew similarly to BMY’s over the last 12 months.
| BMY | GSK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 61% | 2 days ago 59% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 47% |
| MACD ODDS (%) | 3 days ago 45% | 2 days ago 43% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 53% |
| Advances ODDS (%) | 5 days ago 56% | 16 days ago 64% |
| Declines ODDS (%) | 2 days ago 53% | 2 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 63% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 52% | 2 days ago 42% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while GSK’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- GSK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 4 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- GSK’s TA Score: 4 bullish, 7 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.07% price change this week, while GSK (@Pharmaceuticals: Major) price change was -4.97% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -3.39%. For the same industry, the average monthly price growth was -8.55%, and the average quarterly price growth was +8.33%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
GSK is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-3.39% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.